ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2028 EPS estimates for ARS Pharmaceuticals in a research note issued on Thursday, March 20th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings of $1.57 per share for the year, down from their previous forecast of $1.70. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.56. The company had revenue of $86.58 million for the quarter, compared to analysts' expectations of $15.46 million.
Several other research firms have also recently weighed in on SPRY. Raymond James boosted their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a report on Tuesday, January 14th. Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They set an "outperform" rating and a $40.00 target price for the company. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners upped their target price on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Finally, Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $31.00.
Check Out Our Latest Stock Analysis on SPRY
SPRY opened at $12.36 on Monday. The firm has a 50 day moving average price of $12.06 and a 200-day moving average price of $13.05. ARS Pharmaceuticals has a twelve month low of $7.55 and a twelve month high of $18.51. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -24.24 and a beta of 1.03.
A number of hedge funds have recently modified their holdings of SPRY. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of ARS Pharmaceuticals in the third quarter worth approximately $1,120,000. Intech Investment Management LLC bought a new position in shares of ARS Pharmaceuticals during the third quarter worth $239,000. Charles Schwab Investment Management Inc. boosted its position in shares of ARS Pharmaceuticals by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 423,947 shares of the company's stock worth $6,147,000 after acquiring an additional 8,417 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of ARS Pharmaceuticals by 121.1% during the third quarter. The Manufacturers Life Insurance Company now owns 46,854 shares of the company's stock worth $679,000 after acquiring an additional 25,658 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of ARS Pharmaceuticals by 766.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company's stock worth $3,401,000 after acquiring an additional 207,456 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.
In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total value of $615,500.00. Following the completion of the transaction, the director now directly owns 210,346 shares in the company, valued at $2,589,359.26. This represents a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares of the company's stock, valued at approximately $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 159,600 shares of company stock worth $1,866,516 over the last three months. 40.10% of the stock is currently owned by company insiders.
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.